dc.contributor.author | Briassoulis, E. Ch | en |
dc.contributor.author | Pentheroudakis, George | en |
dc.contributor.author | Timotheadou, H. | en |
dc.contributor.author | Rammou, D. | en |
dc.contributor.author | Pavlidis, Nicholas | en |
dc.contributor.author | Fountzilas, George | en |
dc.creator | Briassoulis, E. Ch | en |
dc.creator | Pentheroudakis, George | en |
dc.creator | Timotheadou, H. | en |
dc.creator | Rammou, D. | en |
dc.creator | Pavlidis, Nicholas | en |
dc.creator | Fountzilas, George | en |
dc.date.accessioned | 2018-06-22T09:52:44Z | |
dc.date.available | 2018-06-22T09:52:44Z | |
dc.date.issued | 2004 | |
dc.identifier.uri | https://gnosis.library.ucy.ac.cy/handle/7/41476 | |
dc.description.abstract | We developed a chemotherapy combination regimen based on preclinical data suggesting synchronization of cancer cells in G2/M phase when exposed to irinotecan over a protracted period. This phase I study aimed to determine the toxicity spectrum, and define the dose-limiting toxicity (DLT), maximum tolerated dose (MTD) and recommended optimal dose (ROD) of irinotecan infused over 24 h and followed by a 1-h infusion of 30 mg/m2 docetaxel. Starting dose for irinotecan was 30 mg/m2 and escalation proceeded at 30 mg/m2 increments, in cohorts of three to six patients until the MTD was reached. A dose between the MTD and the previous level was explored to further define the ROD. Thirty-two patients with advanced refractory cancers (median age 64, 19 male) received 190 treatment courses at five dosing levels of irinotecan: 30 mg/m2 (n=6 patients), 60 (n=3), 90 (n=7), 120 (n=8) and 105 (n=8). The MTD and ROD was 120/30 and 105/30 mg/m2. DLTs were diarrhea and neutropenia. Antitumor activity was modest The ROD of biweekly administration of 24-h irinotecan followed by 1-h docetaxel is 105 and 30 mg/m2, respectively. The low hematological toxicity and modest activity observed leave questions concerning the optimal timing of this combination. © 2004 Lippincott Williams & Wilkins. | en |
dc.language.iso | eng | en |
dc.source | Anti-Cancer Drugs | en |
dc.subject | Greece | en |
dc.subject | Article | en |
dc.subject | Human | en |
dc.subject | Humans | en |
dc.subject | Adult | en |
dc.subject | Aged | en |
dc.subject | Female | en |
dc.subject | Middle aged | en |
dc.subject | Advanced cancer | en |
dc.subject | Cancer combination chemotherapy | en |
dc.subject | Chemotherapy | en |
dc.subject | Priority journal | en |
dc.subject | Alopecia | en |
dc.subject | Anemia | en |
dc.subject | Anorexia | en |
dc.subject | Antineoplastic combined chemotherapy protocols | en |
dc.subject | Arthralgia | en |
dc.subject | Bone marrow suppression | en |
dc.subject | Clinical article | en |
dc.subject | Clinical trial | en |
dc.subject | Constipation | en |
dc.subject | Diarrhea | en |
dc.subject | Docetaxel | en |
dc.subject | Drug infusion | en |
dc.subject | Fatigue | en |
dc.subject | Febrile neutropenia | en |
dc.subject | Infection | en |
dc.subject | Leukopenia | en |
dc.subject | Mucosa inflammation | en |
dc.subject | Myalgia | en |
dc.subject | Neutropenia | en |
dc.subject | Taxoids | en |
dc.subject | Thrombocytopenia | en |
dc.subject | Treatment outcome | en |
dc.subject | Antineoplastic activity | en |
dc.subject | Infusions | en |
dc.subject | Intravenous | en |
dc.subject | Drug administration schedule | en |
dc.subject | Fever | en |
dc.subject | Gastrointestinal toxicity | en |
dc.subject | Time factors | en |
dc.subject | Drug exposure | en |
dc.subject | Dose response | en |
dc.subject | Dose-response relationship | en |
dc.subject | Drug | en |
dc.subject | Male | en |
dc.subject | Side effect | en |
dc.subject | Blood toxicity | en |
dc.subject | Camptothecin | en |
dc.subject | Irinotecan | en |
dc.subject | Nausea | en |
dc.subject | Chemotherapy induced emesis | en |
dc.subject | Maximum tolerated dose | en |
dc.subject | Phase 1 clinical trial | en |
dc.subject | Hiccup | en |
dc.subject | Phase i | en |
dc.subject | Phase ii | en |
dc.subject | Cancer cell | en |
dc.subject | Cell cycle g2 phase | en |
dc.subject | Clinical trials | en |
dc.subject | Dizziness | en |
dc.subject | Edema | en |
dc.subject | Headache | en |
dc.subject | Hematologic diseases | en |
dc.subject | Insomnia | en |
dc.subject | Metaphase | en |
dc.subject | Patient selection | en |
dc.subject | Pruritus | en |
dc.subject | Withholding treatment | en |
dc.title | Biweekly administration of 24-h infusion of irinotecan followed by a 1-h infusion of docetaxel: A phase I study | en |
dc.type | info:eu-repo/semantics/article | |
dc.identifier.doi | 10.1097/00001813-200409000-00002 | |
dc.description.volume | 15 | |
dc.description.issue | 8 | |
dc.description.startingpage | 747 | |
dc.description.endingpage | 752 | |
dc.author.faculty | Ιατρική Σχολή / Medical School | |
dc.author.department | Ιατρική Σχολή / Medical School | |
dc.type.uhtype | Article | en |
dc.contributor.orcid | Pavlidis, Nicholas [0000-0002-2195-9961] | |
dc.contributor.orcid | Pentheroudakis, George [0000-0002-6632-2462] | |
dc.gnosis.orcid | 0000-0002-2195-9961 | |
dc.gnosis.orcid | 0000-0002-6632-2462 | |